MS Clinical Trials in Texas

44 active trials · 19 recruiting

44 active multiple sclerosis clinical trials have at least one study site in Texas, 19 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.

Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 21 MS treatment centers in Texas; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.

Active MS trials with sites in Texas

RecruitingPhase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc.

Ublituximab · Placebo

25 states800 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Sponsor: Novartis Pharmaceuticals

Remibrutinib oral treatment · Ocrelizumab

18 states360 participantsDetails ›

RecruitingPhase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsor: Amgen

Ocrelizumab (US) · Ocrelizumab (EU)

17 states444 participantsDetails ›

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Remibrutinib (blinded) · Placebo

10 states1275 participantsDetails ›

RecruitingNA

Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS

Sponsor: The Methodist Hospital Research Institute

Magstim Rapid2 System

1 state29 participantsDetails ›

RecruitingPhase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Ocrelizumab · Placebo for Ocrelizumab

9 states123 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

No Intervention

29 states500 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

Recruiting

Multiple Sclerosis Implementation Network (Registry)

Sponsor: The University of Texas Health Science Center, Houston

2 states2000 participantsDetails ›

RecruitingPhase 3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Sponsor: Celgene

Ozanimod · Fingolimod

9 states194 participantsDetails ›

RecruitingPhase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Autologous Hematopoietic Stem Cell Tr… · Best Available Therapy (BAT)

15 states156 participantsDetails ›

RecruitingPhase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Sponsor: ModernaTX, Inc.

mRNA-1195 · Placebo

5 states180 participantsDetails ›

Recruiting

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

Sponsor: TScan Therapeutics, Inc.

Companion blood samples with procedure

9 states300 participantsDetails ›

Recruiting

NARCOMS Registry: A Multiple Sclerosis Registry

Sponsor: University of Texas Southwestern Medical Center

1 state50000 participantsDetails ›

Recruiting

Care in Multiple Sclerosis (MS)

Sponsor: NYU Langone Health

6 states386 participantsDetails ›

RecruitingNA

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

Sponsor: The University of Texas at Dallas

Transcranial Direct Current Stimulation · Sham transcranial direct current stim…

1 state100 participantsDetails ›

RecruitingNA

Non-invasive BCI-controlled Assistive Devices

Sponsor: University of Texas at Austin

NMES Feedback · Visual Feedback

1 state100 participantsDetails ›

By invitation onlyPhase 1

Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis

Sponsor: University of Texas Southwestern Medical Center

Light therapy

1 state20 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

23 states1011 participantsDetails ›

Closed to new patientsPhase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Disease modifying treatment (DMT)

19 states136 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsor: Novartis Pharmaceuticals

Ofatumumab approved dose · Ofatumumab new dose

24 states196 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

27 states1001 participantsDetails ›

Closed to new patientsPhase 3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Tetanus toxoid (TT) containing vaccin…

32 states1882 participantsDetails ›

Closed to new patientsPhase 3

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Sponsor: TG Therapeutics, Inc.

Ublituximab

14 states1100 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

23 states746 participantsDetails ›

Closed to new patientsPhase 3

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Sponsor: Sanofi

Tolebrutinib · Placebo

27 states2500 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab Placebo

11 states188 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsPhase 4

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Sponsor: University of Texas Southwestern Medical Center

Cladribine

2 states40 participantsDetails ›

Closed to new patientsPhase 2

HB-adMSCs for the Treatment of Patients With Multiple Sclerosis

Sponsor: Hope Biosciences Research Foundation

Autologous HB-adMSCs

1 state10 participantsDetails ›

Closed to new patientsPhase 2

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Sponsor: Zenas BioPharma (USA), LLC

Obexelimab · Placebo

11 states93 participantsDetails ›

Closed to new patientsNA

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Sponsor: Johns Hopkins University

Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…

28 states900 participantsDetails ›

Closed to new patientsNA

MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience

Sponsor: Ad scientiam

MSCopilot Flower mobile application

4 states60 participantsDetails ›

Closed to new patients

Biobank For MS And Other Demyelinating Diseases

Sponsor: Accelerated Cure Project for Multiple Sclerosis

9 states3226 participantsDetails ›

Closed to new patients

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

Sponsor: The Cleveland Clinic

MRI

9 states420 participantsDetails ›

Closed to new patientsPhase 4

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Sponsor: The Cleveland Clinic

Early Highly Effective Therapies Group · Escalation Therapies Group

8 states800 participantsDetails ›

Closed to new patientsNA

MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect

Sponsor: Ad scientiam

MSCopilot® Detect mobile application

10 states336 participantsDetails ›

Closed to new patients

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.

Sponsor: Centre Hospitalier Universitaire de Nīmes

Observational

1 state320 participantsDetails ›

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Active MS trials with sites in Texas

MS trials in other states